We are live on ! Find out more
ALPN

Alpine Immune Sciences Inc

Delisted

ALPN was delisted on the 17th of May, 2024.

26 hedge funds and large institutions have $21.1M invested in Alpine Immune Sciences Inc in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less funds holding

Funds holding: 2826 (-2)

13% less capital invested

Capital invested by funds: $24.2M → $21.1M (-$3.09M)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

60% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 10

Holders
26
Holders Change
-2
Holders Change %
-7.14%
% of All Funds
0.65%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
4
Reduced
10
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$8.99M
BI
2
BVF Inc
California
$6.37M +$1.87M +195,083 +42%
TM
3
Tiger Management
New York
$1.57M
RSCM
4
Rock Springs Capital Management
Maryland
$1.45M
Vanguard Group
5
Vanguard Group
Pennsylvania
$894K -$96.3K -10,045 -10%
SIM
6
Spark Investment Management
New York
$310K -$95.3K -9,945 -24%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$303K -$4.7K -490 -2%
Victory Capital Management
8
Victory Capital Management
Texas
$203K +$202K +21,074 New
BlackRock
9
BlackRock
New York
$187K -$32.2K -3,363 -15%
FPF
10
FNY Partners Fund
New York
$154K -$9.58K -1,000 -20%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$142K +$71.6K +7,474 +102%
Jacobs Levy Equity Management
12
Jacobs Levy Equity Management
New Jersey
$141K -$34.2K -3,570 -20%
ARTA
13
A.R.T. Advisors
New York
$81K -$67.2K -7,008 -45%
Northern Trust
14
Northern Trust
Illinois
$73K -$5.03K -525 -6%
Morgan Stanley
15
Morgan Stanley
New York
$50K +$45.5K +4,751 +1,031%
MML Investors Services
16
MML Investors Services
Massachusetts
$48K
Renaissance Technologies
17
Renaissance Technologies
New York
$35K +$35K +3,650 New
VKH
18
Virtu KCG Holdings
New York
$29K +$29K +3,024 New
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$22K +$4.6K +480 +27%
JP Morgan Chase
20
JP Morgan Chase
New York
$15K +$15.3K +1,600 New
UBS Group
21
UBS Group
Switzerland
$14K +$13.8K +1,445 New
Creative Planning
22
Creative Planning
Kansas
$6K
Barclays
23
Barclays
United Kingdom
$6K +$6.47K +675 New
AIM
24
Acrospire Investment Management
Illinois
$3K -$28.5K -2,978 -91%
Manulife (Manufacturers Life Insurance)
25
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K -$173 -18 -8%

ALPN Hedge Fund Activity: Q2 2017 in Review

26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q2 2017, worth a combined $21.1M — down 13% from $24.2M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ALPN and 7 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 4 added.

The largest buyer was BVF Inc, adding an estimated $1.87M. The largest seller was Panagora Asset Management, exiting entirely with an estimated $429K sold.

  • 26 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q2 2017, down from 28 in Q1 2017.
  • Funds reported $21.1M of Alpine Immune Sciences Inc stock for Q2 2017, down 13% quarter-over-quarter.
  • 7 funds opened new Alpine Immune Sciences Inc positions in Q2 2017 and 9 closed out, a net change of -2 holders.
  • The largest Alpine Immune Sciences Inc buyer in Q2 2017 was BVF Inc, an estimated $1.87M added.
  • The largest Alpine Immune Sciences Inc seller in Q2 2017 was Panagora Asset Management, an estimated $429K sold.

Based on aggregated 13F filings for Q2 2017.